We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Revvity (RVTY) Q2 Earnings
Read MoreHide Full Article
Wall Street analysts expect Revvity (RVTY - Free Report) to post quarterly earnings of $1.14 per share in its upcoming report, which indicates a year-over-year decline of 6.6%. Revenues are expected to be $711.27 million, up 2.8% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Revvity metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Net Sales- Life Sciences' should arrive at $342.32 million. The estimate indicates a change of +9.1% from the prior-year quarter.
The average prediction of analysts places 'Net Sales- Diagnostics' at $365.99 million. The estimate indicates a year-over-year change of -3.2%.
The combined assessment of analysts suggests that 'Organic revenue growth - Diagnostics' will likely reach 3.8%. Compared to the present estimate, the company reported 3.0% in the same quarter last year.
Over the past month, Revvity shares have recorded returns of -0.3% versus the Zacks S&P 500 composite's +5.9% change. Based on its Zacks Rank #3 (Hold), RVTY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Revvity (RVTY) Q2 Earnings
Wall Street analysts expect Revvity (RVTY - Free Report) to post quarterly earnings of $1.14 per share in its upcoming report, which indicates a year-over-year decline of 6.6%. Revenues are expected to be $711.27 million, up 2.8% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Revvity metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Net Sales- Life Sciences' should arrive at $342.32 million. The estimate indicates a change of +9.1% from the prior-year quarter.
The average prediction of analysts places 'Net Sales- Diagnostics' at $365.99 million. The estimate indicates a year-over-year change of -3.2%.
The combined assessment of analysts suggests that 'Organic revenue growth - Diagnostics' will likely reach 3.8%. Compared to the present estimate, the company reported 3.0% in the same quarter last year.
View all Key Company Metrics for Revvity here>>>Over the past month, Revvity shares have recorded returns of -0.3% versus the Zacks S&P 500 composite's +5.9% change. Based on its Zacks Rank #3 (Hold), RVTY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .